


# Four out of five patients with heart failure are eligible for treatment with an SGLT2 inhibitor

November 16 2020

---



Credit: American Heart Association

Analysis of data from a dedicated heart failure registry reveals four out of five patients with heart failure with reduced ejection fraction (HFrEF) could be considered for treatment with dapagliflozin, an sodium glucose co-transporter-2 (SGLT2) inhibitor, according to an

analysis to be presented at the American Heart Association's Scientific Sessions 2020. The study will be published simultaneously today in *JAMA Cardiology*.

"Despite accelerating [scientific discoveries](#), few patients with [heart failure](#) are being treated with the best available treatment options in 2020," said Muthiah Vaduganathan, M.D., M.P.H., first author of the study, a cardiologist at Brigham and Women's Hospital and faculty at Harvard Medical School. "While SGLT2 inhibitors were first developed for treatment of [diabetes](#), these therapies have now been recognized to reduce mortality, prevent worsening heart failure events, and improve health-related quality of life in patients with HFrEF, including among those without diabetes."

Clinical trials evaluating novel therapies are often conducted in highly selected groups of patients, raising questions regarding the applicability of the trial results to "real world" patients in clinical practice. The objective of the study was to determine the proportion of patients with heart failure who would meet eligibility for treatment with dapagliflozin, as outlined by the U.S. Food and Drug Administration's May 2020 approval of dapagliflozin for patients with HFrEF. While SGLT2 inhibitors were initially developed for the management of type 2 diabetes, dapagliflozin is the first SGLT-2 inhibitor to be approved for use for heart failure, irrespective of diabetes status.

The study evaluated data from over 150,000 patients hospitalized for HFrEF at over 400 hospital centers across the U.S. participating in the American Heart Association's [Get with The Guidelines](#)-Heart Failure (GWTG-HF) quality improvement initiative from 2014 to 2019. The researchers found:

- 80% of patients in the registry met the FDA criteria for HF treatment with dapagliflozin;

- A similarly high proportion of patients with type 2 diabetes (~75%) and without type 2 diabetes (~85%) met [eligibility criteria](#);
- Advanced kidney disease (eGFR

Citation: Four out of five patients with heart failure are eligible for treatment with an SGLT2 inhibitor (2020, November 16) retrieved 20 December 2022 from <https://medicalxpress.com/news/2020-11-patients-heart-failure-eligible-treatment.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.